Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020 - 2021)
Agios Pharmaceuticals (AGIO) posted Liabilities from Discontinued Operations of 34533000.0 for Q1 2021, down 10.21% on a QoQ basis from 38459000.0 in Q4 2020.
Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020 - 2021) Analysis & Trends
Agios Pharmaceuticals' Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 34533000.0 for Q1 2021.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 34533000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was 34533000.0 (changed N/A YoY) and the FY2020 annual result came in at 38459000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 34533000.0 for Q1 2021 at Agios Pharmaceuticals, down from 38459000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 38459000.0 in Q4 2020 and bottomed at 34533000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 34.53 Mn |
| Mar 31, 2021 | 34.53 Mn |
| Dec 31, 2020 | 38.46 Mn |
| Dec 31, 2020 | 38.46 Mn |